{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:37:45Z","timestamp":1793043465547,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40121-017-0153-2","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T08:19:23Z","timestamp":1490775563000},"page":"199-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review"],"prefix":"10.1007","volume":"6","author":[{"given":"Jennifer N.","family":"Lashinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oryan","family":"Henig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"issue":"Pt 12","key":"153_CR1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1099\/jmm.0.46747-0","volume":"55","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55(Pt 12):1619\u201329.","journal-title":"J Med Microbiol"},{"issue":"2","key":"153_CR2","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/cc4869","volume":"10","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):R48.","journal-title":"Crit Care"},{"issue":"4","key":"153_CR3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1086\/502205","volume":"24","author":"MV Villegas","year":"2003","unstructured":"Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977\u20132000. Infect Control Hosp Epidemiol. 2003;24(4):284\u201395.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"153_CR4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nrmicro1789","volume":"5","author":"L Dijkshoorn","year":"2007","unstructured":"Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939\u201351.","journal-title":"Nat Rev Microbiol"},{"key":"153_CR5","unstructured":"Centers for Disease Control and Prevention. Tracking CRE Infections. 2013. http:\/\/www.cdc.gov\/hai\/organisms\/cre\/TrackingCRE.html . Accessed Oct 2016."},{"issue":"2","key":"153_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4068\/cmj.2014.50.2.37","volume":"50","author":"UJ Kim","year":"2014","unstructured":"Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant acinetobacter infections. Chonnam Med J. 2014;50(2):37\u201344.","journal-title":"Chonnam Med J."},{"issue":"5","key":"153_CR7","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/AAC.01665-09","volume":"54","author":"T Reddy","year":"2010","unstructured":"Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H, et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother. 2010;54(5):2235\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"153_CR8","first-page":"3291","volume":"70","author":"SE Cheah","year":"2015","unstructured":"Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70(12):3291\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"153_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.diagmicrobio.2012.04.002","volume":"73","author":"AM Queenan","year":"2012","unstructured":"Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis. 2012;73(3):267\u201370.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"153_CR10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12879-015-1297-x","volume":"15","author":"O Oikonomou","year":"2015","unstructured":"Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K, Zakynthinos E, et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis. 2015;15:559.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"153_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jhm.2477","volume":"11","author":"MD Zilberberg","year":"2016","unstructured":"Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11(1):21\u20136.","journal-title":"J Hosp Med."},{"issue":"Suppl 6","key":"153_CR12","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/cid\/ciu706","volume":"59","author":"M Castanheira","year":"2014","unstructured":"Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014;59(Suppl 6):S367\u201373.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"153_CR13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","volume":"60","author":"L Vidal","year":"2007","unstructured":"Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60(2):247\u201357.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"153_CR14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","volume":"68","author":"AT Freire","year":"2010","unstructured":"Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140\u201351.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"153_CR15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/eri.13.14","volume":"11","author":"JM Pogue","year":"2013","unstructured":"Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther. 2013;11(4):383\u201393.","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"Suppl 6","key":"153_CR16","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1093\/cid\/ciu594","volume":"59","author":"JM Pogue","year":"2014","unstructured":"Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis. 2014;59(Suppl 6):S388\u201393.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"153_CR17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01615-10","volume":"56","author":"SM Bhavnani","year":"2012","unstructured":"Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"153_CR18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","volume":"395","author":"F Nguyen","year":"2014","unstructured":"Nguyen F, Starosta AL, Arenz S, Sohmen D, Donhofer A, Wilson DN. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395(5):559\u201375.","journal-title":"Biol Chem"},{"issue":"3","key":"153_CR19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijantimicag.2016.05.017","volume":"48","author":"P Dimitriadis","year":"2016","unstructured":"Dimitriadis P, Protonotariou E, Varlamis S, Poulou A, Vasilaki O, Metallidis S, et al. Comparative evaluation of minocycline susceptibility testing methods in carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48(3):321\u20133.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"153_CR20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","volume":"45","author":"ME Falagas","year":"2015","unstructured":"Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2015;45(5):455\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"153_CR21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cpt1973145852","volume":"14","author":"H Macdonald","year":"1973","unstructured":"Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 1973;14(5):852\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"153_CR22","doi-asserted-by":"crossref","unstructured":"Lomovskaya O SD, Rubio-Aparicio D, Nelson K, Dudley M. TetB testing and its absence identifies minocycline (MINO) susceptible isolates of Acinetobacter baumannii (ACB). In: Presented at: IDWeek; October 26\u201330, 2016; New Orleans, LA.","DOI":"10.1093\/ofid\/ofw172.1591"},{"issue":"1","key":"153_CR23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00284-015-0829-3","volume":"71","author":"S Montana","year":"2015","unstructured":"Montana S, Vilacoba E, Traglia GM, Almuzara M, Pennini M, Fernandez A, et al. Genetic variability of AdeRS two-component system associated with tigecycline resistance in XDR-Acinetobacter baumannii isolates. Curr Microbiol. 2015;71(1):76\u201382.","journal-title":"Curr Microbiol"},{"key":"153_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/5584_2015_5001","volume":"897","author":"S Pournaras","year":"2016","unstructured":"Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In vitro activity of tigecycline against Acinetobacter baumannii: global epidemiology and resistance mechanisms. Adv Exp Med Biol. 2016;897:1\u201314.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"153_CR25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dkq218","volume":"65","author":"M Hornsey","year":"2010","unstructured":"Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65(8):1589\u201393.","journal-title":"J Antimicrob Chemother"},{"key":"153_CR26","unstructured":"Sun D R-AD, Tsivkovski R, King P, Dudley M, Lomovskaya O. Tigecycline (TIG) but NOT Minocycline (MINO) Readily selects for clinically relevant efflux-mediated resistance (R) in acinetobacter (ACB). In: Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10\u201313, 2013; Denver, CO."},{"issue":"2","key":"153_CR27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jiac.2014.10.009","volume":"21","author":"C Rizek","year":"2015","unstructured":"Rizek C, Ferraz JR, van der Heijden IM, Giudice M, Mostachio AK, Paez J, et al. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. J Infect Chemother. 2015;21(2):114\u20137.","journal-title":"J Infect Chemother."},{"key":"153_CR28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-0711-12-24","volume":"12","author":"GA Denys","year":"2013","unstructured":"Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin Microbiol Antimicrob. 2013;12:24.","journal-title":"Ann Clin Microbiol Antimicrob."},{"issue":"9","key":"153_CR29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","volume":"60","author":"ZA Qureshi","year":"2015","unstructured":"Qureshi ZA, Hittle LE, O\u2019Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295\u2013303.","journal-title":"Clin Infect Dis"},{"key":"153_CR30","doi-asserted-by":"crossref","unstructured":"Colton B, McConeghy KW, Schreckenberger PC, Danziger LH. I.V. minocycline revisited for infections caused by multidrug-resistant organisms. Am J Health Syst Pharm. 2016;73(5):279\u201385.","DOI":"10.2146\/ajhp150290"},{"issue":"1","key":"153_CR31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijantimicag.2015.11.006","volume":"47","author":"V Thamlikitkul","year":"2016","unstructured":"Thamlikitkul V, Tiengrim S, Seenama C. Comparative in vitro activity of minocycline and selected antibiotics against carbapenem-resistant Acinetobacter baumannii from Thailand. Int J Antimicrob Agents. 2016;47(1):101\u20132.","journal-title":"Int J Antimicrob Agents"},{"key":"153_CR32","doi-asserted-by":"crossref","unstructured":"Lomovskaya O NK, Rubio-Aparicio D, Sun D, Giffith DC, Dudley MN. Minocycline acitivity is enhanced by polymyxin B in tetB-containing isolates of Acinetobacter baumannii. In: Presented at: IDWeek; October 26\u201330, 2016; New Orleans, LA.","DOI":"10.1093\/ofid\/ofw172.1589"},{"issue":"5","key":"153_CR33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.8.5.532","volume":"8","author":"PG Welling","year":"1975","unstructured":"Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA. Pharmacokinetics of minocycline in renal failure. Antimicrob Agents Chemother. 1975;8(5):532\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"153_CR34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1440-1681.1974.tb00552.x","volume":"1","author":"S Carney","year":"1974","unstructured":"Carney S, Butcher RA, Dawborn JK, Pattison G. Minocycline excretion and distribution in relation to renal function in man. Clin Exp Pharmacol Physiol. 1974;1(4):299\u2013308.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"153_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/23.1.123","volume":"23","author":"FP Maesen","year":"1989","unstructured":"Maesen FP, Davies BI, van den Bergh JJ. Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother. 1989;23(1):123\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"153_CR36","unstructured":"Minocin\u00ae (Minocycline), USP [package insert]. Monza (Milan), Italy: Triax Pharmaceuticals; 2010."},{"issue":"3","key":"153_CR37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF01969570","volume":"7","author":"I Sklenar","year":"1977","unstructured":"Sklenar I, Spring P, Dettli L. One-dose and multiple-dose kinetics of minocycline in patients with renal disease. Agents Actions. 1977;7(3):369\u201377.","journal-title":"Agents Actions"},{"issue":"9","key":"153_CR38","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","volume":"40","author":"J Bergeron","year":"1996","unstructured":"Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40(9):2226\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"153_CR39","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01499-05","volume":"50","author":"MW Olson","year":"2006","unstructured":"Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O\u2019Connell J, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006;50(6):2156\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"153_CR40","unstructured":"Tarazi ZSM, Dudley MN, Griffith DC. Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model. In: Presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 18-21, 2015; San Diego, CA."},{"key":"153_CR41","doi-asserted-by":"crossref","unstructured":"Jankowski CA, Balada-Llasat J-M, Raczkowski M, Pancholi P, Goff DA. A stewardship approach to combating multidrug-resistant Acinetobacter baumannii infections with minocycline. Infect Dis Clin Pract 2012;20:4.","DOI":"10.1097\/IPC.0b013e318245d50a"},{"issue":"Suppl 6","key":"153_CR42","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/cid\/ciu593","volume":"59","author":"DA Goff","year":"2014","unstructured":"Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program\u2019s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clin Infect Dis. 2014;59(Suppl 6):S381\u20137.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"153_CR43","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s00134-003-1811-2","volume":"29","author":"GC Wood","year":"2003","unstructured":"Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003;29(11):2072\u20136.","journal-title":"Intensive Care Med"},{"key":"153_CR44","doi-asserted-by":"crossref","unstructured":"Griffith ME, Yun HC, Horvath LL, Murray CK. Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus Complex. Infect Dis Clin Pract. 2008;16:4.","DOI":"10.1097\/ipc.0b013e318159d595"},{"issue":"6","key":"153_CR45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0885066610377975","volume":"25","author":"JD Chan","year":"2010","unstructured":"Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25(6):343\u20138.","journal-title":"J Intensive Care Med"},{"issue":"5","key":"153_CR46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijantimicag.2009.06.021","volume":"34","author":"E Bishburg","year":"2009","unstructured":"Bishburg E, Bishburg K. Minocycline\u2014an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009;34(5):395\u2013401.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"153_CR47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3760\/cma.j.issn.0366-6999.20132047","volume":"127","author":"F Ning","year":"2014","unstructured":"Ning F, Shen Y, Chen X, Zhao X, Wang C, Rong Y, et al. A combination regimen of meropenem, cefoperazone-sulbactam and minocycline for extensive burns with pan-drug resistant Acinetobacter baumannii infection. Chin Med J. 2014;127(6):1177\u20139.","journal-title":"Chin Med J"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-017-0153-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T09:24:06Z","timestamp":1719134646000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-017-0153-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1007\/s40121-017-0153-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]}}}